Cited by 221RNA Interference and Gene DeliveryDendrimers and Hyperbranched PolymersNanoparticle-Based Drug Delivery

Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I

Cheng, Qiang, Wei, Tuo, Jia, Yuemeng, Farbiak, Lukas, Zhou, Kejin, Zhang, Shuyuan, Wei, Yonglong, Zhu, Hao +1 more·2018·Advanced Materials

Abstract

mRNA‐mediated protein replacement represents a promising concept for the treatment of liver disorders. Children born with fumarylacetoacetate hydrolase (FAH) mutations suffer from Hepatorenal Tyrosinemia Type 1 (HT‐1) resulting in renal dysfunction, liver failure, neurological impairments, and cancer. Protein replacement therapy using FAH mRNA offers tremendous potential to cure HT‐1, but is currently hindered by the development of effective mRNA carriers that can function in diseased livers. Structure‐guided, rational optimization of 5A2‐SC8 mRNA‐loaded dendrimer lipid nanoparticles (mDLNPs) increases delivery potency of FAH mRNA, resulting in functional FAH protein and sustained normalization of body weight and liver function in FAH −/− knockout mice. Optimization using luciferase mRNA produces DLNP carriers that are efficacious at mRNA doses as low as 0.05 mg kg −1 in vivo. mDLNPs transfect > 44% of all hepatocytes in the liver, yield high FAH protein levels (0.5 mg kg −1 mRNA), and are well tolerated in a knockout mouse model with compromised liver function. Genetically engineered FAH −/− mice treated with FAH mRNA mDLNPs have statistically equivalent levels of TBIL, ALT, and AST compared to wild type C57BL/6 mice and maintain normal weight throughout the month‐long course of treatment. This study provides a framework for the rational optimization of LNPs to improve delivery of mRNA broadly and introduces a specific and viable DLNP carrier with translational potential to treat genetic diseases of the liver.

Integrity signals

Registry

Crossref · 10.1002/adma.201805308

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The therapeutic potential of mRNA-based protein replacement therapies has been tested in other metabolic disorders in preclinical studies, including hereditary tyrosinaemia type I, acute intermittent porphyria, Fabry disease, Crigler-Najjar syndrome type 1, α1 antitrypsin deficiency, methylmalonic acidaemia/aciduria, arginase deficiency, citrin deficiency and glycogen storage disease type I.

    “The therapeutic potential of mRNA-based protein replacement therapies has also been tested in other metabolic disorders in preclinical studies, including hereditary tyrosinaemia type I (HTI)142, acute intermittent porphyria222,223, Fabry disease224,225, Crigler–Najjar syndrome type 1 (ref.226), α1 antitrypsin deficiency227, methylmalonic acidaemia/aciduria228, arginase deficiency229, citrin defic”

    From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [142]

  • In Fah knockout mice i.v. administered hFAH mRNA loaded DLNPs every 3 days for a month, hFAH expression was elevated in the liver.

    “The mice were i.v. administrated with hFAH mRNA loaded DLNPs every 3 days for a month, during which hFAH expression was elevated in the liver.[162]”
  • Long-term use of nitisinone increases the risks of developing hepatic neoplasms and liver failure.

    “However, long-term use of nitisinone increases the risks of developing hepatic neoplasms and liver failure.[162]”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J.
Affiliations
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
Siegwart, Daniel J.
Venue
Advanced Materials
Publisher
Wiley
Published
2018-10-25
Volume
30
Issue
52
Pages
e1805308-e1805308
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W2898487406
Cited by
221
References
49
Citations by year
2026: 16 · 2025: 30 · 2024: 36 · 2023: 38 · 2022: 32 · 2021: 30 · 2020: 26 · 2019: 13
FWCI
6.13
Type
journal article
Language
en
Open access
closed
Locations
  • Advanced Materials (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (CA150245P3)
  • American Cancer Society (RSG‐17‐012‐01)
  • Cancer Prevention and Research Institute of Texas (R1212)
  • Welch Foundation (I‐1855)
  • National Institutes of Health (R01CA190525)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
fumarylacetoacetate hydrolase, mRNA delivery, liver-directed gene therapy, hepatocyte transfection, hereditary liver disease
MeSH terms
Animals, Disease Models, Animal, Hydrolases, Liver, Mice, Inbred C57BL, Mice, Transgenic, Random Allocation, RNA, Messenger, Genetic Therapy, Tyrosinemias, Dendrimers, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review